The post INJ Price Prediction: Target $6.50-$7.00 by January 2025 Despite Current Bearish Momentum appeared on BitcoinEthereumNews.com. Alvin Lang Dec 18, 2025The post INJ Price Prediction: Target $6.50-$7.00 by January 2025 Despite Current Bearish Momentum appeared on BitcoinEthereumNews.com. Alvin Lang Dec 18, 2025

INJ Price Prediction: Target $6.50-$7.00 by January 2025 Despite Current Bearish Momentum



Alvin Lang
Dec 18, 2025 10:30

INJ price prediction shows potential 42-52% upside to $6.50-$7.00 range within 4-6 weeks, despite current oversold conditions at $4.59 support level.

INJ Price Prediction: Injective Primed for Recovery Despite Near-Term Weakness

Injective Protocol (INJ) finds itself at a critical juncture as we approach the end of 2025, trading near its 52-week low of $4.59 while technical indicators paint a mixed picture for the coming weeks. Our comprehensive INJ price prediction analysis suggests a potential recovery rally toward $6.50-$7.00, though immediate downside risks persist.

INJ Price Prediction Summary

INJ short-term target (1 week): $5.15-$5.43 (+12-18% from current levels)
Injective medium-term forecast (1 month): $6.20-$7.00 range (+35-52% potential upside)
Key level to break for bullish continuation: $5.57 (EMA 26 resistance)
Critical support if bearish: $4.53 (immediate support) and $4.56 (analyst bearish target)

Recent Injective Price Predictions from Analysts

The latest wave of analyst forecasts reveals a cautiously optimistic consensus for Injective’s price trajectory. MEXC’s conservative INJ price prediction of $4.91 for the short term appears already outdated given current market dynamics, while Coinbase’s longer-term Injective forecast of $6.31 over five years suggests modest growth expectations.

More bullish perspectives emerge from Blockchain.News analysts, who project an INJ price target ranging from $6.50 to $7.00 in the medium term, citing emerging MACD momentum despite current bearish readings. This aligns with Bitcoin Insider’s assessment that INJ is approaching the psychological $6.00 level amid increased trading volume.

The analyst consensus reveals a clear divide between conservative institutional forecasts and more aggressive technical-based predictions, with most agreeing that current price levels around $4.59 represent oversold conditions ripe for reversal.

INJ Technical Analysis: Setting Up for Oversold Bounce

Current Injective technical analysis reveals classic oversold conditions that often precede significant price rebounds. The RSI reading of 30.56 sits in neutral territory but approaching oversold levels, while the MACD histogram at -0.0412 shows bearish momentum that may be exhausting itself.

The Bollinger Bands positioning tells a compelling story for our INJ price prediction. With INJ trading at a %B position of -0.0239, the token sits just below the lower band at $4.63, indicating extreme oversold conditions. Historically, such positioning has led to mean reversion moves toward the middle band at $5.43.

Volume analysis on Binance shows $6.27 million in 24-hour trading, suggesting institutional interest remains despite the recent 4.51% decline. The Average True Range of $0.47 indicates significant volatility that could facilitate rapid price movements in either direction.

Injective Price Targets: Bull and Bear Scenarios

Bullish Case for INJ

The primary bullish scenario for our Injective forecast centers on a break above the EMA 26 resistance at $5.57. This level represents the first major hurdle for any sustainable recovery, with successful reclaim likely triggering algorithmic buying and momentum traders.

Our INJ price target sequence follows this pattern: initial resistance at $5.57, followed by the SMA 20 at $5.43, then the critical $6.19 level (SMA 50). A sustained break above $6.19 opens the door to analyst targets of $6.50-$7.00, representing a 42-52% upside from current levels.

The bullish case strengthens if MACD turns positive above the signal line, currently sitting at -0.3836. Such a crossover would confirm momentum shift and support our medium-term Injective forecast of reaching $7.00 by late January 2025.

Bearish Risk for Injective

Downside risks remain significant if INJ fails to hold current support levels. The immediate support at $4.53 aligns with today’s low, making it a critical level to monitor. A break below could trigger stop-loss orders and accelerate decline toward $4.56, matching analyst bearish targets.

The most concerning scenario involves a break below the 52-week low of $4.59, which could signal capitulation selling and potential decline toward $4.00-$4.20 range. The distance from the SMA 200 at $10.81 shows the magnitude of the current downtrend, requiring significant catalyst for reversal.

Should You Buy INJ Now? Entry Strategy

Current price levels present a compelling risk-reward setup for strategic accumulation. Our buy or sell INJ recommendation leans bullish with specific entry criteria: consider initial positions at current levels around $4.59, with additional buying on any dip to $4.53 support.

Risk management remains crucial given the bearish MACD momentum. Set stop-loss orders below $4.50 to limit downside exposure, representing roughly 2% risk from current entry points. Position sizing should remain conservative until technical indicators confirm trend reversal.

For aggressive traders, consider scaling into positions with 25% allocation at current levels, 50% if price tests $4.53 support, and final 25% on confirmed break above $5.15 (EMA 12). This approach allows participation in potential recovery while managing downside risk.

INJ Price Prediction Conclusion

Our comprehensive analysis suggests INJ is positioned for a significant recovery rally over the next 4-6 weeks, with high confidence in reaching $6.20-$6.50 range and medium confidence in testing $7.00 levels. The combination of oversold technical conditions, analyst price targets, and critical support holding creates a favorable setup for the Injective forecast.

Key indicators to monitor include MACD signal line crossover, RSI movement above 40, and most importantly, sustained trading above the $5.15 EMA 12 level. Failure to reclaim this level within the next week would delay our bullish timeline and potentially invalidate the recovery scenario.

Timeline expectations center on initial recovery to $5.43 within 7-10 days, followed by progression toward $6.20-$7.00 range through late January 2025, contingent on broader cryptocurrency market stability and successful technical breakouts.

Image source: Shutterstock

Source: https://blockchain.news/news/20251218-price-prediction-target-inj-650-700-by-january-2025-despite

Market Opportunity
Injective Logo
Injective Price(INJ)
$4,705
$4,705$4,705
-1,95%
USD
Injective (INJ) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Fundstrat’s Internal Report Contradicts CIO Tom Lee’s Bold Crypto Forecasts

Fundstrat’s Internal Report Contradicts CIO Tom Lee’s Bold Crypto Forecasts

The post Fundstrat’s Internal Report Contradicts CIO Tom Lee’s Bold Crypto Forecasts appeared on BitcoinEthereumNews.com. Key Points: Fundstrat internal report
Share
BitcoinEthereumNews2025/12/21 13:19
SEC Backs Nasdaq, CBOE, NYSE Push to Simplify Crypto ETF Rules

SEC Backs Nasdaq, CBOE, NYSE Push to Simplify Crypto ETF Rules

The US SEC on Wednesday approved new listing rules for major exchanges, paving the way for a surge of crypto spot exchange-traded funds. On Wednesday, the regulator voted to let Nasdaq, Cboe BZX and NYSE Arca adopt generic listing standards for commodity-based trust shares. The decision clears the final hurdle for asset managers seeking to launch spot ETFs tied to cryptocurrencies beyond Bitcoin and Ether. In July, the SEC outlined how exchanges could bring new products to market under the framework. Asset managers and exchanges must now meet specific criteria, but will no longer need to undergo drawn-out case-by-case reviews. Solana And XRP Funds Seen to Be First In Line Under the new system, the time from filing to launch can shrink to as little as 75 days, compared with up to 240 days or more under the old rules. “This is the crypto ETP framework we’ve been waiting for,” Bloomberg research analyst James Seyffart said on X, predicting a wave of new products in the coming months. The first filings likely to benefit are those tracking Solana and XRP, both of which have sat in limbo for more than a year. SEC Chair Paul Atkins said the approval reflects a commitment to reduce barriers and foster innovation while maintaining investor protections. The move comes under the administration of President Donald Trump, which has signaled strong support for digital assets after years of hesitation during the Biden era. New Standards Replace Lengthy Reviews And Repeated Denials Until now, the commission reviewed each application separately, requiring one filing from the exchange and another from the asset manager. This dual process often dragged on for months and led to repeated denials. Even Bitcoin spot ETFs, finally approved in Jan. 2024, arrived only after years of resistance and a legal battle with Grayscale. According to Bloomberg ETF analyst Eric Balchunas, the streamlined rules could apply to any cryptocurrency with at least six months of futures trading on the Coinbase Derivatives Exchange. That means more than a dozen tokens may now qualify for listing, potentially unleashing a new wave of altcoin ETFs. SEC Clears Grayscale Large Cap Fund Tracking CoinDesk 5 Index The SEC also approved the Grayscale Digital Large Cap Fund, which tracks the CoinDesk 5 Index, including Bitcoin, Ether, XRP, Solana and Cardano. Alongside this, it cleared the launch of options linked to the Cboe Bitcoin US ETF Index and its mini contract, broadening the set of crypto-linked derivatives on regulated US markets. Analysts say the shift shows how far US policy has moved. Where once regulators resisted digital assets, the latest changes show a growing willingness to bring them into the mainstream financial system under established safeguards
Share
CryptoNews2025/09/18 12:40
Bank of Canada cuts rate to 2.5% as tariffs and weak hiring hit economy

Bank of Canada cuts rate to 2.5% as tariffs and weak hiring hit economy

The Bank of Canada lowered its overnight rate to 2.5% on Wednesday, responding to mounting economic damage from US tariffs and a slowdown in hiring. The quarter-point cut was the first since March and met predictions from markets and economists. Governor Tiff Macklem, speaking in Ottawa, said the decision was unanimous. “With a weaker economy […]
Share
Cryptopolitan2025/09/17 23:09